Home » Stocks » GLYC

GlycoMimetics, Inc. (GLYC)

Stock Price: $2.03 USD 0.02 (1.00%)
Updated Aug 3, 2021 2:12 PM EDT - Market open
Market Cap 104.11M
Revenue (ttm) 2.22M
Net Income (ttm) -57.64M
Shares Out 50.70M
EPS (ttm) -1.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day August 3
Last Price $2.03
Previous Close $2.01
Change ($) 0.02
Change (%) 1.00%
Day's Open 2.01
Day's Range 2.00 - 2.04
Day's Volume 99,350
52-Week Range 1.96 - 4.40

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that clinicians have treated the first patient in a Phase 1b/2 study evaluating the company's lead drug candidate, upr...

1 week ago - Business Wire

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that clinicians at University of California (UC) Davis Comprehensive Cancer Center initiated dosing of the first patie...

3 weeks ago - Business Wire

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that Chief Executive Officer Rachel King will provide a company overview at the Jefferies 2021 Virtual Healthcare Con...

2 months ago - Business Wire

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that clinicians at Washington University School of Medicine in St. Louis have dosed the first patient in an investigat...

2 months ago - Business Wire

Investors need to pay close attention to GlycoMimetics (GLYC) stock based on the movements in the options market lately.

2 months ago - Zacks Investment Research

There are some investors who buy U.S.-listed stocks that are trading below their liquidation value because they believe they can gain from these kinds of investments after the market has reappraised the...

Other stocks mentioned: GRAY, ODT
2 months ago - GuruFocus

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the quarter ended March 31, 2021 and highlighted recent company events. Cash and cash equival...

3 months ago - Business Wire

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that it will host a conference call and webcast to report first quarter financial results on Monday, May 3, 2021, at ...

3 months ago - Business Wire

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announces that an abstract presenting the results of a recent preclinical study on the therapeutic effects of GMI-1757, a new gl...

3 months ago - Business Wire

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announces that a Phase 1b trial of GMI-1359, being conducted at Duke University Cancer Center, showed evidence of on-target effe...

3 months ago - Business Wire

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announces that an abstract presenting the interim analysis of a Phase 1b proof-of-concept study of GMI-1359, the Company's dual ...

4 months ago - Business Wire

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics (Nasdaq: GLYC) today announced that Apollomics has dosed the first patient in China in a Phase 1 clinical trial of APL-106 (uproleselan injection) for the ...

4 months ago - Business Wire

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the fourth quarter and year ended December 31, 2020, and highlighted recent Company events, i...

5 months ago - Business Wire

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that executives from the Company plan to participate in three virtual healthcare conferences in March. More informati...

5 months ago - Business Wire

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that it will host a conference call and webcast to report fourth quarter and year-end 2020 financial results on Tuesd...

5 months ago - Business Wire

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced the promotion of Eric Feldman, M.D., to Senior Vice President and Chief Medical Officer. Dr. Feldman joined the Compan...

5 months ago - Business Wire

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics (Nasdaq: GLYC) today in an oral presentation at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition disclosed new data reinforcing ...

7 months ago - Business Wire

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics' (Nasdaq: GLYC) product candidate uproleselan — when added to a combination therapy of venetoclax and a hypomethylating agent (HMA) — was shown today in an...

7 months ago - Business Wire

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that CEO Rachel King plans to present an overview of the company at the upcoming Stifel 2020 Virtual Healthcare Confe...

8 months ago - Business Wire

GlycoMimetics' (GLYC) CEO Rachel King on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the third quarter ended September 30, 2020, and highlighted recent company events. Cash and c...

8 months ago - Business Wire

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that three abstracts including data from the Company's clinical and research portfolio have been accepted for oral pre...

8 months ago - Business Wire

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its third quarter financial results on Friday, November 6, 2...

9 months ago - Business Wire

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that new post hoc analyses of the Phase 3 RESET study evaluating the efficacy of rivipansel, its wholly-owned product ...

9 months ago - Business Wire

GlycoMimetics is undervalued based on its AML therapy potential.

9 months ago - Seeking Alpha

GlycoMimetics' (GLYC) rivipansel gets a Rare Pediatric Disease designation by the FDA for the treatment of SCD in patients 18 years old and younger.

9 months ago - Zacks Investment Research

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that the U.S. Food and Drug Administration (FDA) has granted the Company a Rare Pediatric Disease designation for rivi...

9 months ago - Business Wire

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc.

10 months ago - Business Wire

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc.

10 months ago - Business Wire

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc.

11 months ago - Business Wire

GlycoMimetics, Inc. (GLYC) CEO Rachel King on Q2 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc.

1 year ago - Business Wire

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc.

1 year ago - Business Wire

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (the “Company”) (NASDAQ:GLYC) today announced that the compensation committee of the Company’s Board of Directors approved the grant on July 6, 2020 ...

1 year ago - Business Wire

GlycoMimetics (GLYC) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

1 year ago - Zacks Investment Research

GlycoMimetics (GLYC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

1 year ago - Zacks Investment Research

GlycoMimetics, Inc. (GLYC) CEO Rachel King on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

GlycoMimetics' Focus Is On AML Therapy

1 year ago - Seeking Alpha

GlycoMimetics' (GLYC) CEO Rachel King on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Pharma sector wins in October, making these ETFs and stocks winners.

Other stocks mentioned: DERM, IRWD, PJP, PPH, RIGL, XPH
1 year ago - Zacks Investment Research

Biotech concern GlycoMimetics fell sharply in early August when its out-licensed candidate rivipansel flunked a Phase 3 trial.

1 year ago - Seeking Alpha

Much of GlycoMimetics' value was supposed to be in the uproleselan AML therapy.

1 year ago - Seeking Alpha

Falling Knives are companies whose share prices have fallen more than 59% over the past year, generating the interest of investors as they can make huge gains if they bounce back.

Other stocks mentioned: NCNA
1 year ago - GuruFocus

Investors need to pay close attention to GlycoMimetics (GLYC) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research

GlycoMimetics Inc. (NASDAQ: GLYC) shares were crushed on Monday after the firm announced late-stage results from its sickle cell disease (SCD) trial in conjunction with Pfizer Inc.

1 year ago - 24/7 Wall Street

Shares of GlycoMimetics Inc. GLYC, -1.30% fell 53% in premarket trade Monday after the company announced Friday evening that a Phase 3 trial of a sickle-cell disease drug, developed in partnership with ...

1 year ago - Market Watch

GlycoMimetics (NASDAQ: GLYC) announced late Friday afternoon that Pfizer's (NYSE: PFE) Phase 3 clinical trial evaluating Rivipansel in sickle cell disease has not met its primary or key secondary endpoi...

1 year ago - Benzinga

GlycoMimetics, Inc. (GLYC) CEO Rachel King on Q2 2019 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

GlycoMimetics, Inc. (GLYC) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

2 years ago - Zacks Investment Research

GlycoMimetics has an outlicensed lead candidate targeting VOC in SCD patients.

2 years ago - Seeking Alpha

About GLYC

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's drug candidate include rivipansel, a pan-selectin antagonist for the treatment of vaso-occlusive crisis in sickle cell disease. It is also developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as Phase 3 trial to treat relapsed/refractory A... [Read more...]

Industry
Biotechnology
IPO Date
Jan 10, 2014
CEO
Rachel King
Employees
54
Stock Exchange
NASDAQ
Ticker Symbol
GLYC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for GlycoMimetics stock is "Buy." The 12-month stock price forecast is 10.67, which is an increase of 425.62% from the latest price.

Price Target
$10.67
(425.62% upside)
Analyst Consensus: Buy